Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 12/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217930 | 0.90 | KCNJ6 (0.48) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5219606 | 0.88 | MAPT (0.44) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL27714640 | 0.87 | MAPT (0.43) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5217998 | 0.86 | BLM (0.50) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5215989 | 0.84 | MAPT (0.63) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5218672 | 0.84 | KDR (0.53) | BLM | |
| SCHEMBL5215826 | 0.84 | MAPT (0.47) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5222457 | 0.83 | RAB9A (0.47) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5218299 | 0.83 | MAPT (0.53) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5214990 | 0.82 | MAPT (0.41) | MAPTLMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101115528-A | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogs thereof | ACHILLION PHARMACEUTICALS INC (US) | 2008-01-30 | — | — | CN | claimed |
| EP-1809380-A2 | INHIBITORS OF HIV-1 CAPSID FORMATION: SUBSTITUTED ARYL AMINOMETHYL THIAZOLE UREAS AND ANALOGUES THEREOF | Achillion Pharmaceuticals, Inc. (US) | 2007-07-25 | — | — | EP | claimed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | claimed |
| WO-2006053323-A2 | INHIBITORS OF HIV-1 CAPSID FORMATION: SUBSTITUTED ARYL AMINOMETHYL THIAZOLE UREAS AND ANALOGUES THEREOF | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ACHILLION PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | claimed |
| CN-101115528-A | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogs thereof | ACHILLION PHARMACEUTICALS INC (US) | 2008-01-30 | — | — | CN | disclosed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | disclosed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | disclosed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | disclosed |
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ACHILLION PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ZC3HAV1, CD4, ACIN1 | HSD17B10 4158/4885MAPT 420/4885LMNA 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.